anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are implicated in the development and progression of various tumors. The aim of this study was to investigate the effects of circ_SMA4 in Gastrointestinal Stromal Tumors (GISTs) malignant progression. Human circRNAs microarray analysis was conducted to identify differentially expressed (DE) circRNAs in GISTs. The effect of circ_SMA4 on cell proliferation, invasion, migration, and apoptosis was assessed in both in vitro and in vivo settings. Dual-luciferase reporter assay, RT-qPCR, Western-blot, and rescue assay were employed to confirm the interaction between circ_SMA4/miR-494-3p/ KIT axis. The results revealed that circ_SMA4 was significantly upregulated in GISTs, and exhibited high diagnostic efficiency with an AUC of 0.9824 (P < 0.01). circ_SMA4 promoted cell proliferation, invasion, migration, while inhibiting apoptosis in GISTs cells, both in vitro and in vivo. Silencing circ_SMA4 partially inhibited GISTs malignant progression. Additionally, circ_SMA4 acted as a competing endogenous RNA (ceRNA) by targeting miR-494-3p, and KIT was identified as a functional gene for miR-494-3p in GISTs. Furthermore, the results confirmed that circ_SMA4/miR-494-3p/ KIT axis plays a role in activating the JAK/STAT signaling pathway in GISTs. Therefore, for the first time, we have identified and emphasized that circ_SMA4 is significantly upregulated and plays an oncogenic role in GISTs by sponging miR-494-3p to activate the KIT/JAK/STAT pathway. These findings underscore circ_SMA4 may serve as a novel diagnostic biomarker and therapeutic target for GISTs.
In Phase I, participants will participate in pilot and usability tests of the curriculum prototype. For the pilot test, teachers and students will use the curriculum prototype and then be interviewed about it. For the usability test, students and teachers will use the revised curriculum and be interviewed/complete short survey. Teachers will provide consent and students will have parental consent and their own assent.

In Phase II, a group randomized trial will be conducted during Spring semester 2020 among 9th grade student in 27 high schools in the Hillsborough County Public School system randomly assigned to treatment and control (14 treatment and 13 control). All students will complete a pretest survey. Students in two health classes in treatments schools will participate in the REAL media Plus curriculum and complete a short immediate posttest survey to rate their experience. All students will then complete two posttests. Students will have parental consent and provide their own assent.
Unmet nursing care may occur due to systemic, institutional or nursing-related reasons. Reasons such as insufficient staff and equipment, excessive workload (Pereira et al., 2020), confusion between disciplines, and failure to prioritize care play an important role in missed care (Chaboyer et al., 2021; Dutra \& Guirardello, 2021; Kılıç et al., 2023). In summary, while improvements should be made in nursing care practices to ensure patient safety and quality of care, systemic improvements should also be made. In order to make these improvements, it should be determined what the missed nursing care experienced and perceived in the clinical field is and what causes them. This research was conducted to determine the perceptions of intensive care nurses about unmet nursing care. This study is a qualitative design research conducted with intensive care nurses. In the study, a purposeful sample selection was made in accordance with the qualitative research approach. The number of participants was determined according to data saturation and is based on the volunteering of a total of 20 intensive care nurses. During the interview, the participants were asked a personal information form and expert opinion on the subject, as well as in-depth interview questions in a semi-structured information form consisting of eight questions.
Abstract of the Disclosure The invention relates to novel carboxamido derivatives of 5-oxo-5H-1,3,4-thiadiazolo[3,2-a]pyrimidines of formula I       and the pharmaceutically acceptable salts thereof.  Typical values of RI in-clude hydrogen, C1-C6 alkyl, pyridyl and morpholino.  Typical values of R2 include hydrogen and methyl.  Typical values of R3 include pyridyl, thiazolyl and benzothiazolyl.  The compounds display valuable anti-inflammatory and analgesic properties. The compounds have a high therapeutic index.
Provided are a lipid nanoparticle for efficiently delivering a nucleic acid drug, a method for preparing same, and use thereof. The lipid nanoparticle comprises a vector and an encapsulated nucleic acid. The vector comprises a composite ionizable lipid, an auxiliary phospholipid, a cholesterol substance, and a pegylated lipid. The nucleic acid comprises one or more of mRNA, circular RNA, siRNA, microRNA, an antisense nucleic acid, and a plasmid. The composite ionizable lipid comprises an ionizable lipid with the capability of efficiently entering cells, and an ionizable lipid with a long alkyl chain and the capability of efficient membrane fusion. The composite ionizable lipid can significantly improve the mRNA expression efficiency of commercial four-component LNPs by means of synergism. The lipid nanoparticle facilitates the efficient expression of the nucleic acid drug entrapped therein after intramuscular administration, thus efficiently activating humoral and cell-mediated immune responses.
PURPOSE:To obtain a tacky adhesive sheet having excellent feeling and flexibility and having tacky adhesive layer directly and firmly bonded to a substrate, by laminating and bonding a tacky adhesive agent composed of a styrene-diene- styrene block copolymer to a substrate sheet composed of a specific resin composition. CONSTITUTION:The objective tacky adhesive sheet can be produced by laminating and bonding (A) a tacky adhesive agent composed of a styrene-diene-styrene block copolymer to (B) a substrate sheet composed of a resin composition containing (i) 100pts.wt. of a polyurethane-PVC graft copolymer and (ii) 20-80 pts.wt. of an ethylene-vinyl acetate copolymer. The objective sheet is suitable e.g. as a plaster.
The number of people infected by HIV-1 worldwide continues to increase. However, antiretroviral therapy is largely unavailable in low- and middle- income countries where risk of infection is very high. The development of a safe and effective vaccine to prevent HIV infection is urgently needed. This study will evaluate the effectiveness, safety, and immunogenicity of an experimental multiclade HIV vaccine, VRC-HIVDNA016-00-VP, followed by an adenovirus-vectored vaccine boost, VRC-HIVADV014-00-VP, in HIV uninfected adults. Both vaccines code for proteins from HIV subtypes A, B, and C, which together represent 75% to 85% of new HIV infections in the world. Adenoviral type 5-based vaccines have improved induction of HIV-specific CD8 cytotoxic T-lymphocyte cell responses, which correlate with lower HIV burden (viral load) and slower disease progression in primates and in HIV-1 infected people whose disease does not progress over the long term. The purpose of this study is to determine the safety and effectiveness of and immune response to a series of multiclade DNA vaccine injections followed by a booster injection of a multiclade adenovirus vaccine against HIV-1 infection in healthy adults at risk for HIV infection in North and South America, the Caribbean, and Africa.

This study will last from about 3 years to 5 years, because the length of the study depends on how quickly people enroll and how quickly during the study new HIV-1 infections occur. Study participants will be randomly assigned to receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP, for a total of four injections of vaccine or four injections of placebo. Injections will occur at study entry and Weeks 4, 8, and 24. Prior to the study injections, participants will have their vital signs and weight measured, and blood collection will occur. Participants will be observed in the clinic for at least 30 minutes after each injection for immediate reactions to the vaccines. At all injection visits, HIV risk-reduction counseling, HIV risk assessment, pregnancy prevention counseling, and training on how to use memory cards will also occur. For 3 to 7 days after each injection, participants will be asked to record information about injection site pain, redness, size, swelling, temperature, general well-being, and headaches on their memory cards. Additional study visits will occur on Weeks 1, 12, 28, 48, 72, 96, 120, and 144. At these visits, physical examinations, blood collection, and social impact questionnaires may also be done. Any study participants who become infected with HIV while on the study will be monitored for at least 72 weeks after diagnosis or at least 12 weeks after the study reaches its primary evaluation time point (whichever is longer). The study investigators are committed to providing access to local standard of care and treatment to those study participants who are found to be HIV-1 infected.
INTRODUCTION: Many of the injury mechanisms that cause mild traumatic brain injury (mTBI) also create forces commonly associated with whiplash, resulting in cervical pain injury. The prevalence of associated neck pain with mTBI is not well established. There is a strong indication that injury to the cervical spine may aggravate, cause, and/or impact recovery of symptoms and impairments associated with the concussive event and its primary effect on the brain. The purpose of this study is to help identify the prevalence of ensuing cervical pain within 90 days of a previously documented mTBI and to examine the role of neck pain during concurrent concussive symptoms, in a military population stationed at a large military installation.
MATERIALS AND METHODS: This retrospective design utilized a de-identified dataset using predetermined search and filter criteria, which included male active duty service members (SMs), 20 to 45 years of age, who received medical care at any clinic on Fort Liberty (Fort Bragg, NC) during fiscal year (FY) 2012 to FY 2019, with documented cervicalgia and mTBI (via the International Classification of Diseases, 9th and 10th Revision, Clinical Modification codes), verified using electronic medical records. The final dataset served as the basis for subject sampling and was analyzed to determine the total number of documented cervicalgia and mTBI diagnoses. Results are presented as descriptive statistics. Approval for this study was received from the Andrews University Office of Research (18-097) and the Womack Army Medical Center Human Protections Office.
RESULTS: Between FY 2012 and FY 2019, 14,352 unique SMs accessed a Fort Bragg, NC health care facility, at least once (Table I). Overall, 52% of SMs diagnosed with cervicalgia were found to have a previously diagnosed mTBI during the 90 days before the cervicalgia diagnosis. In contrast, the prevalence of same-day cervicalgia and mTBI diagnosis was <1% (Table IV). The prevalence of isolated cervicalgia diagnosis at any time during the reporting period was 3%, whereas isolated mTBI diagnosis was 1% (Table III).
CONCLUSIONS: Over 50% of SMs diagnosed with cervicalgia had sustained a documented mTBI within 90 days prior, whereas less than 1% were diagnosed with cervicalgia at the time of initial primary care or emergency room encounter following the mTBI event. This finding suggests that the close anatomical and neurophysiological connections between the head and the cervical spine are both likely to be impacted through the same mechanism of injury. Delayed evaluation (and treatment) of the cervical spine may contribute to lingering post-concussive symptoms. Limitations of this retrospective review include the inability to assess the causality of the relationship between neck pain and mTBI, as only the existence and strength of the prevalence relationship can be identified. The outcome data are exploratory and intended to identify relationships and trends that may suggest further study across installations and across mTBI populations.
Methods for stimulating gamma globin gene expression in a mammalian cell comprising contacting the cell with a compound selected from valeric acid and certain isomers, derivatives or salts thereof, including isovaleric acid, 4-pentynoic acid and methylthioacetic acid, or an inhibitor of a short chain fatty acyl CoA dehydrogenase, or an activator of protein kinase C are disclosed. The methods of the invention are particularly useful for ameliorating .beta.-globin disorders, such as sickle cell anemia or .beta.-thalassemia. The method of the invention can also be used to prevent or ameliorate malaria in a mammal. The compounds of the invention can also be used to stimulate differentiation of a cell. Pharmaceutical compositions of the acive compounds of the invention are also disclosed. Screening assays for identifying agents that stimulate gamma globin gene expression in an erythroid cell, stimulate cell differentiation or stimulate transport of a short chain fatty acid, or derivative or salt thereof, into cells are also disclosed.
Methods, systems and devices for linking devices to tracking devices is provided. One method includes scanning, by an activity tracking device, for a semi-unique identifier broadcasted by a device. The method connects the device with the activity tracking device after the semi-unique identifier is found to be of the device by the activity tracking device. The activity tracking device is configured to communicate with the device to obtain a device identification (ID) of the device. The method then automatically linking the device to the activity tracking device when the device ID of the device matches a copy of the device ID stored in the activity tracking device. In one example, the tracking devices operate as a master and the devices operate as a slave.
PURPOSE: To provide a device for the removal of inconvenience of carrying a medicine or taking medicine frequently before others, etc. CONSTITUTION: In the case for producing this device at the place where a tooth exists, a hole 11 is formed in an abutment. The hole is filled with a liquid medicine, or a cartridge filled with the liquid medicine is placed in the hole. The hole is covered with a jacket crown 9 in a removable manner. Further, the jacket crown has a piece of porous ceramic 9a or is pierced with many fine holes so that the liquid medicine flows out into the oral cavity. In the case of a place where a tooth does not exist, a small hole is formed at a pontic, artificial tooth or denture base. A cartridge filled with the liquid medicine or a troche is placed in the small hole.
This is a Phase I/II randomized study for subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-L, an autologous vaccine comprised of autologous Oxidized tumor Cell Lysate (OC-L) administered by intradermal/subcutaneous injection in combination with Ampligen (poly-l:poly-C12U), a Toll-like receptor 3 agonist. Study duration is 24 months. This study has two Phases eligible subjects enrolled in Phase 1 will receive the OC-L admixed with Montanide ISA 51 with intravenous Ampligen. Subjects enrolled in Phase II will be randomized to two ARMS. This randomized design will allow for the unbiased evaluation and comparison of immune response among the 2 treatment arms. patients will be randomized (10 per treatment arm) in blocks of size 4 or 6, such that treatment assignment will be balanced after each group of 4 or 6 patients has been randomized. ARM A 10 patients will receive OC-L. Arm b 10 patients will receive OC-L with Ampligen. Following each vaccination, subjects in Phase I and Arm B will be given intravenous Ampligen 3 times starting 2-3 days after each vaccine administration. All subjects will receive vaccine on Day 0, 14, 28, 42 and 56. Subjects will receive Prevnar on day 0 and day 14. Subjects will be treated till exhaustion of OC-L or disease progression whichever occurs first subjects will be contacted every 6 months for up to 5 years and then annually for survival. The OC-L study product is manufactured and quality tested at Cell and Vaccine Production Facility and then released to IDS, where it will be admixed with Montanide ISA 51 VG on day of vaccination.
PROBLEM TO BE SOLVED: To obtain a superoxide dismutase (SOD) derivative capable of improving pharmacological effect through raising the blood half-life of SOD and low in active oxygen toxicity due to H2 O2 as a reaction product from SOD itself, and to provide a method for producing the SOD derivative. SOLUTION: This SOD derivative is a SOD modified with oligomerized keratin, esp. an oligomerized keratin incorporated with crosslink group through reaction with a lower aliphatic dicarboxylic acid (e.g. modified with succinylated keratin). This modified SOD can be obtained by reaction of a SOD with a crosslink group-incorporated keratin formed by reaction between a keratin hydrolyzate and an aliphatic lower dicarboxylic acid. This SOD derivative has excellent mitigating effect on paraquat toxicity, also exhibiting high efficacy on wound curing and further, exhibiting excellent erasing effect on active oxygen toxicity.
Irinotecan/platinum regimens are emerging as standard treatments for patients with extensive-stage disease. The irinotecan/carboplatin doses that will be used in this study have been used in two previous Phase II SCLC trials, and were found to be extremely well tolerated (Thompson et al. 2005; Spigel et al. 2007). Adding a novel, minimally toxic agent to this regimen may further enhance efficacy in this patient population without contributing to toxicity. This trial will evaluate the use of sunitinib following 6 cycles of treatment with chemotherapy in the treatment of SCLC.

The trial will be performed under the leadership of SCRI, a community-based, multi-center, clinical trial organization.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events. However, the precise mechanisms beyond glycemic control are not fully understood. The objective of this study was to determine the role of PDGF (platelet-derived growth factor)-related signaling in empagliflozin-mediated inhibition of neointima formation.
METHODS AND RESULTS: Adult male nondiabetic Wistar rats were subjected to carotid artery balloon injury. Empagliflozin (30 mg/kg per day) was administered by oral gavage for 18 days beginning 4 days before surgery. The in vitro effects of empagliflozin on rat aortic vascular smooth muscle cell (VSMC) proliferation and migration were also determined. Empagliflozin attenuated balloon injury-induced neointima formation in carotid arteries. In VSMCs, empagliflozin attenuated PDGF-BB-induced proliferation and migration. Moreover, empagliflozin-treated VSMCs did not undergo apoptosis or cytotoxic death. Empagliflozin suppressed PDGF-related signaling, including phosphorylation of PDGF receptor β, Akt, and STAT3 (signal transducer and activator of transcription 3). Overactivation of PDGF signaling attenuated empagliflozin-mediated inhibition of VSMC function. SGLT2 mRNA levels in rat VSMCs were undetectable, and SGLT2 silencing did not alter the empagliflozin-mediated effects, supporting the SGLT2-independent effects of empagliflozin on VSMC.
CONCLUSIONS: This study highlights the crucial role of suppressing PDGF-related signaling in mediating the beneficial effects of empagliflozin on neointima formation and VSMC function, which are independent of SGLT2 and glycemic control. Our study provides a novel mechanistic aspect of empagliflozin for the prevention of vascular stenosis disorders.
A formulation for oral administration, in particular to ruminants. Effective substances such as nutrients and medications should be released after a delay or slowly after they have been administered orally. In particular in the case of ruminants, very little or none should be released in the rumen. Suitable coatings are costly and, in particular, are unsuitable for administration in large quantities. Known coatings of this kind also entail the disadvantage of physiological incompatibility and/or are not permitted under current legislation. The new coating contains thinner zones and/or nominal break points that accelerate release compared to essentially even coatings. It is preferred that sharp-edged particles, such as pellets, be coated, when the coating is so configured that it can break away along the edges after oral administration. Preferred are coatings made up of two layers, the inner layer containing a filler and a film-forming medium, and the outer layer containing only film-forming medium.
Chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in the United States, affects millions of people around the world. COPD, which can include both emphysema and chronic bronchitis, affects the lungs making it very difficult to breathe. Cigarette smoking is the most common risk factor for developing COPD; however, only 15% to 20% of smokers develop COPD in their lifetimes. The onset of COPD also varies greatly from person to person; while some people do not develop respiratory symptoms until later in life, there are others who develop severe COPD at a very early age. Prior research has led to the discovery of the alpha-1 antitrypsin protein deficiency in association with COPD development. This discovery has generated further interest toward studying other genetic factors which may also affect an individual's likelihood of developing COPD. Therefore, the purpose of the Boston Early-Onset COPD study is to gain a better understanding of COPD risk factors in order to establish new possible methods of treatment for people affected by COPD.

For this study we are enrolling individuals affected with severe COPD (52 years old or younger with an FEV1 \< 40%) and their family members. Each participant will attend one study visit that involves a respiratory questionnaire, a breathing test, and blood draw. This visit can be completed at the participant's home, in the hospital, or by long distance data collection (phone interview, local breathing tests, and local blood draw with mailed samples), whichever is preferred.
Cosmetic composition comprises myrrh essential oil as an active agent to improve the firmness of the skin and/or to provide a cleansing effect. An independent claim is included for a process for cosmetic care, preferably for refirming and/or cleansing the skin, comprising applying the composition on the body skin. ACTIVITY : Dermatological. MECHANISM OF ACTION : Angiogenesis stimulator. The effect of the composition to stimulate angiogenesis was tested in endothelial cells. The result showed that the composition exhibited an angiogenesis stimulation of + 100%.
Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.